Print page |
Email page
| 
Download PDF
|
Add to briefcase
« Previous Release | Next Release »
PETALUMA, Calif., Sep 06, 2007 (BUSINESS WIRE) --
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) announced today that its president and chief executive officer, Hoji Alimi, will be presenting at the First Albany Capital Regenerative Technologies Conference on September 11, 2007, at 1:40 p.m. (EDT) at the Yale Club of New York. Mr. Alimi will provide an overview of the company, its clinical programs and the most recent quarter. For more information on this event please visit http://www.fac.com.
About Oculus
Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a solution of non-irritating, small molecule oxychlorine compounds with the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores. It has been commercialized outside of the U.S. for the treatment of infected wounds. It is currently under evaluation for the treatment of mildly infected diabetic ulcers under the brand name of Dermacyn™ in the U.S.
Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe, Latin America and Japan through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V., Oculus Technologies of Mexico, S.A. de C.V. and Oculus Japan K.K. Oculus' website is www.oculusis.com.
SOURCE: Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences, Inc. Director of Public and Investor Relations Dan McFadden, 425-753-2105 dmcfadden@oculusis.com or The Ruth Group Investors: Sara Ephraim, 646-536-7002 sephraim@theruthgroup.com or Media: Jason Rando, 646-536-7025 jrando@theruthgroup.com Janine McCargo, 646-536-7033 jmccargo@theruthgroup.com
Copyright Business Wire 2007
News Provided by COMTEX